Key points from article :
The International Institute of Longevity (IIOL) has announced a strategic relaunch in 2024, with Tina Woods as the new Executive Director. Originally founded in 2018 by Joanna Bensz and Prince Michael of Liechtenstein, the IIOL now aims to set global standards for longevity clinics, ensuring evidence-based practices and consumer protection.
The institute is expanding its role from a think tank to a platform for professional practice, emphasising policy advocacy, collaboration with wellness industries, and the integration of scientific advancements like personalised medicine, genomics, and AI into practical healthcare solutions.
One of the IIOL's key focuses is on creating best practices for longevity clinics and promoting decentralised human trials. This approach aims to accelerate innovation and improve therapeutic outcomes.
The advisory board, led by Dr. Eric Verdin, includes leading experts in longevity science who will guide the institute’s efforts to bridge scientific research with real-world applications. By setting industry standards, IIOL seeks to ensure safe, high-quality care and enhance the credibility of the rapidly growing longevity sector.
The relaunch comes at a crucial time, as public interest in health optimisation has surged, and investor engagement in biotech and longevity services has increased. However, the sector faces challenges, including the lack of regulatory oversight, which can lead to unsubstantiated claims. IIOL aims to address these concerns by advocating for scientifically validated approaches.
IIOL will present its strategy at the Biomarkers of Aging Consortium event in Boston and the Roundtable of Longevity Clinics at the Buck Institute later in 2024. According to Dr. Verdin, this initiative is crucial for shaping the future of longevity clinics, ensuring patient safety, and improving the overall reputation of this evolving field of clinical care.
